Bayer Navigates Dual Legal Challenges for Roundup Weedkiller

Bayer, the agrochemical manufacturer, is at a critical juncture, facing two significant legal developments concerning its Roundup weedkiller. The U.S. Supreme Court has agreed to hear an appeal from the company regarding thousands of state lawsuits alleging Roundup causes cancer, specifically non-Hodgkin's lymphoma. Concurrently, Bayer has announced a proposed $7.25 billion settlement aimed at resolving a substantial portion of these claims.

These twin developments — a landmark Supreme Court review and a massive settlement offer — underscore the immense legal pressure on Bayer.

Background of Allegations and Litigation

Bayer acquired Monsanto, the original maker of Roundup, in 2018. Since then, the company has been embroiled in extensive litigation. Bayer has faced approximately 181,000 to 200,000 Roundup-related claims in the U.S., predominantly from residential users. These lawsuits allege that the company failed to adequately warn consumers about a potential link between the weedkiller and cancer.

Bayer vehemently disputes these allegations, asserting that glyphosate, Roundup's main ingredient, does not cause non-Hodgkin's lymphoma. The Environmental Protection Agency (EPA) has supported this stance, stating that glyphosate is unlikely to be carcinogenic to humans when used as directed. Consequently, the federally approved label for Roundup does not include a cancer warning. However, research has indicated an association between glyphosate and cancer, creating a significant point of contention in the legal battles.

Supreme Court Appeal

The Supreme Court's decision to review Bayer's appeal will focus on a pivotal legal question: whether the EPA's approval of Roundup without a cancer warning should preempt, or prevent, state court claims that allege a failure to warn.

This appeal originates from a Missouri case where a jury awarded $1.25 million to an individual who developed non-Hodgkin’s lymphoma after applying Roundup. Bayer is pushing for the Supreme Court's intervention due to conflicting rulings by lower courts, including a 2024 decision by the 3rd U.S. Circuit Court of Appeals that favored Bayer. Notably, the Supreme Court had previously declined to review a similar appeal from Bayer in 2022, which stemmed from a California case resulting in an award of over $86 million.

Bayer CEO Bill Anderson stated, "it is time for the U.S. legal system to establish that companies should not be punished under state laws for complying with federal warning label requirements."

The Trump administration had previously supported Bayer's position in court. Further bolstering this stance, North Dakota and Georgia have passed laws designed to shield pesticide manufacturers from state failure-to-warn lawsuits when their products comply with federal labeling requirements. The timeline for arguments in the Supreme Court case remains undetermined, potentially occurring in the spring or at the start of the next court term in October.

Proposed $7.25 Billion Settlement

In a separate but related development, Bayer has announced a proposed $7.25 billion settlement to resolve thousands of U.S. lawsuits alleging Roundup caused cancer. This agreement, filed in St. Louis Circuit Court in Missouri, requires court approval. The funds would be distributed through annual payments into a special fund for up to 21 years.

Individual payouts under the proposed settlement would vary significantly, based on factors such as the plaintiff's exposure to Roundup, their age at diagnosis, and the severity of their non-Hodgkin lymphoma:

• An agricultural worker with extensive exposure and diagnosed with an aggressive form of lymphoma before age 60 could receive an average of $165,000.
• A residential user diagnosed with a less aggressive form between ages 60 and 77 might receive around $20,000.
• Those diagnosed at age 78 or older could receive an average of $10,000.

Attorney Christopher Seeger, representing current claimants, stated the agreement aims to ensure meaningful compensation for both current and future patients. However, not all parties are in agreement. Attorney Matt Clement, representing approximately 280 plaintiffs, indicated that many of his clients might opt out, describing the proposed payouts as "exceedingly too small."

Bayer states that this proposed settlement would reduce its financial risk regardless of the Supreme Court's ruling and assures plaintiffs of compensation. The company also noted that mounting legal costs have impacted its ability to continue selling Roundup in U.S. agricultural markets. In the past, Bayer had allocated $16 billion to settle existing cases, highlighting the ongoing financial strain of this litigation.

Product Adjustments

In response to the legal pressures and public concern, Bayer has made significant adjustments to its product line. The company has ceased using glyphosate in Roundup products sold for residential lawn and garden use in the U.S.

However, glyphosate remains an ingredient in agricultural products, which are designed for use with genetically modified seeds resistant to the weedkiller. This application supports increased agricultural production and soil conservation through reduced tilling. Bayer has indicated it might consider withdrawing glyphosate from U.S. agricultural markets if the lawsuits persist, signaling a potential further shift in its product strategy.